Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

United States.

Net loss for the first quarter of 2009 was approximately $4.6 million, compared to a net loss of approximately $8.0 million for the first quarter of 2008. Net loss per share attributable to common stockholders was $0.26 per share and $0.46 per share for the three months ended March 31, 2009 and 2008, respectively, based on weighted average shares outstanding of 17,568,600 and 17,468,395 respectively.

Cash, cash equivalents and short-term investments were approximately $18.8 million at March 31, 2009, compared to $24.5 million at December 31, 2008.

Stephen Ghiglieri, CFO, commented, "We have focused our cash resources to prosecute our MAA and NDA for Qutenza and to support strategies for obtaining adequate reimbursement for Qutenza in the United States, while deferring further clinical development of Qutenza, NGX-1998 and our preclinical prodrug development programs. As a result of our conservative cost management strategy, we believe that our cash runway is sufficient to last at least until December 31, 2009. Potential near-term proceeds from a European commercial partnership, which we expect to finalize in the first half of 2009, would provide additional runway and have not been accounted for in our current cash forecast. As we pursue European and U.S. commercial partnerships, and other non-equity based sources of funding, we do not currently intend to raise equity capital in the public markets at our present valuation."

Development Update

Currently, NeurogesX is primarily focused on completing the development through regulatory approval, of Qutenza for patients with PHN in the United States and for peripheral neuropathic pain in non-diabetic adults in the E.U.

The CHMP's positive opinion recommending E.U. approval of Qutenza for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination wi
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... A new research platform uses a laser ... structures undergoing stress and heating, an approach ... for microelectronics and batteries., This new technique, ... how heating and the surface stress of ... have discussed the merits of surface-stress influence ...
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... TE 70, TE 77, TE 70 PWR, TE 77 PWR ... outstanding electrophoretic transfer results using low current and voltage with a minimal amount of ... Units available with and without built-in power supplies to give maximum flexibility , ... of proteins from polyacrylamide gels in less than 1 h , ...
... Key words: ... LC-MS/MS • reversed-phase chromatography (RPC) • strong cation exchange (SCX) ... , ... brain tissue. The trypsin-digested tissue was separated by strong cation ...
... Key words: Micronucleus ... , ... analysis of micronuclei formation resulting from DNA strand breakage (clastogens) or ... screening of new drug candidates. Manual scoring of micronucleus assays is ...
Cached Biology Technology:ECL Semi-dry Blotters 22D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 22D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 32D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 42D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 52D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 6Analysis of in vitro micronucleus assays using the IN Cell Analyzer 3000 Micronuclei Formation Analysis Module 2Analysis of in vitro micronucleus assays using the IN Cell Analyzer 3000 Micronuclei Formation Analysis Module 3Analysis of in vitro micronucleus assays using the IN Cell Analyzer 3000 Micronuclei Formation Analysis Module 4Analysis of in vitro micronucleus assays using the IN Cell Analyzer 3000 Micronuclei Formation Analysis Module 5
(Date:8/29/2014)... nucleus, chromosomal DNA is tightly bound to structural ... chromatin. Until about two decades ago, histones were ... material around which the glamorous DNA strands were ... appreciation for how DNA/histone interactions govern gene expression. ... studying the sequence of the genome from cancer ...
(Date:8/29/2014)... the Tibetan plateau -- the largest topographic anomaly above ... its profound effect on climate and its reflection of ... Bulletin , Katharine Huntington and colleagues employ a cutting-edge ... and fossil snail shells to investigate the uplift history ... Views range widely on the timing of surface uplift ...
(Date:8/28/2014)... of America (ESA) is pleased to announce the selection ... the Society. Honorary Membership acknowledges those who have served ... in the affairs of the Society that has reached ... by the ESA Governing Board and then voted on ... at the Awards Ceremony at Entomology 2014, ESA,s Annual ...
Breaking Biology News(10 mins):'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Fred Baxendale selected as Honorary Member of the Entomological Society of America 2
... The 2010 Frost & Sullivan Europe Product ... Systems is presented to Fingerprint Cards AB (FPC). ... (Logo:  http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO) "For more than a ... industry with the prime focus on designing and ...
... 2010 A new study conducted by a researcher ... Taub Center for Social Policy Studies in Israel reports ... than Americans and residents of other OECD (Organization for ... most recent data, from 2005, the average American life ...
... -- The red, metal-laden sludge that escaped a containment pond ... the help of carbon sequestration, says an Indiana University Bloomington ... The bauxite residue now covers 40 square kilometers south of ... Hungarians and injured at least 150. The residue also has ...
Cached Biology News:Frost & Sullivan Honours Fingerprint Cards AB with Product Line Strategy Award 2Frost & Sullivan Honours Fingerprint Cards AB with Product Line Strategy Award 3Frost & Sullivan Honours Fingerprint Cards AB with Product Line Strategy Award 4Life expectancy higher in Israel than in US, according to Ben-Gurion U. researcher 2Can Hungary's red sludge be made less toxic with carbon? 2
AVOID FREEZE/THAW CYCLES. Recognizes the UCP-2 protein....
... The new Vivaspin 2 bridges the gap ... centrifugal concentrators. This device combines the speed ... internal surface and membrane area for superior ... with a choice of PES, Cellulose Triacetate ...
... Recognizes VAMP-2 (Vesicle-Associated Membrane ... epitope does not share homology ... REACTIVITIES: It is expected ... react with human, Macaca multata ...
... Transporter 2 (VMAT2). An antibody made to ... band at ~55 kDa in postnuclear supernatants ... in wild type cells (2). Some additional ... were also detected and remain unaffected by ...
Biology Products: